Trial Profile

A clinical trial assessing ERNA-101

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 20 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ERNA 101 (Primary)
Indications Ovarian cancer
Focus Adverse reactions

Most Recent Events

20 May 2025 New trial record
14 May 2025 According to Ernexa Therapeutics media release, company announced the formation of ErnexaTX2, a wholly owned subsidiary based in Texas to support continued development of ERNA-101, ERNA-101 remains on track for IND-enabling studies in 2025, with first-in-human studies targeted for 2026;

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com